Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg
Adamas Pharmaceuticals (Nasdaq: ADMS) announced the appointment of Spyros Papapetropoulos to its Board of Directors, effective immediately. Papapetropoulos brings over 20 years of experience in neurology, having previously held leadership roles at Acadia, Teva, Pfizer, and others. This change comes with the retirement of Ivan Lieberburg, who served since 2004 and contributed significantly to multiple NDA submissions. Chairman David L. Mahoney and CEO Neil F. McFarlane expressed optimism about the future, highlighting Papapetropoulos's expertise in neurodegenerative diseases as a valuable asset.
- Appointment of Spyros Papapetropoulos expected to enhance strategic direction with expertise in neurology.
- Potential for improved shareholder value through Papapetropoulos's extensive experience in drug development.
- Retirement of Ivan Lieberburg may lead to continuity concerns given his long tenure and critical contributions.
EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board.
“I would like to sincerely thank Ivan for his dedicated service to Adamas since 2004. He played a critical role through multiple successful NDA submissions and our evolution into a successful commercial organization. We wish him well,” said David L. Mahoney, Chairman, Adamas. “We are pleased to have Spyros join us at this next stage of growth. As a seasoned research and development leader, he will be an outstanding addition to our board.”
“Spyros’ extensive experience within neurodegenerative diseases and movement disorders, along with his track record of bringing meaningful therapies to market ideally position him to bring an important perspective to the board. I look forward to his contributions as we continue to deliver on our mission for patients and unlock shareholder value,” added Neil F. McFarlane, CEO.
“I am delighted to join Adamas at this exciting time in the journey towards being a leading neurology company,” said Spyros Papapetropoulos. “I very much look forward to being part of the company’s future growth and continued success.”
Throughout his career, Spyros has led multiple pharmaceutical development programs resulting in successful regulatory filings and product launches. Spyros is a board-certified Neurologist trained in London, UK, and has authored more than 160 peer-reviewed publications. Additionally, Spyros has served on various U.S. government and non-profit committees on healthcare and biomedical research innovation.
About Adamas
At Adamas, our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact:
Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com
Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com
FAQ
Who is Spyros Papapetropoulos and what is his role at Adamas Pharmaceuticals?
Why did Ivan Lieberburg retire from Adamas Pharmaceuticals?
What impact might Spyros Papapetropoulos have on Adamas Pharmaceuticals?
When was Spyros Papapetropoulos appointed to the board?
